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background:  Intracoronary infusion of the mobilized peripheral blood stem cells (mobPBSCs) after administration of granulocyte-colony 
stimulating factor (G-CSF) was proved to be effective in improving myocardial contractility and reducing infarct volume in patients with acute 
myocardial infarction in our previous clinical trials. In order to augment therapeutic efficacy, we tested the effect of priming mobPBSCs with 
Erythropoietin (EPO).
methods:  We used mobPBSCs obtained from healthy volunteers after subcutaneous injection of G-CSF. mobPBSCs were sorted into EPO receptor 
(EPOR) (+) and (-) cells to measure the effect of EPO, and we used mobPBSCs as a whole to check the clinical applicability of EPO-primed 
mobPBSCs. After EPO (10 IU/ml) priming, the downstream pathway of EPOR and the altered expression of vasculogenic molecules in mobPBSCs were 
investigated. Also, cytokines in the 36-hour culture media of mobPBSCs were checked. We used Matrigel plug assay and athymic nude mice hindlimb 
ischemia assay for in vivo models.
results:  About 40% of mobPBSCs were EPOR (+) and responded to 6-hour EPO priming by increasing the expression of vasculogenic cytokines or 
growth factors (IL8, IL10, bFGF, PDGF, MMP9) as well as adhesion molecules (integrin aV, b1, b2, b8). Downstream signaling pathways after EPOR 
were JAK2 and Akt. By EPO priming of mobPBSCs as a whole, whole mobPBSCs also responded by increasing the expression of vasculogenic factors 
and integrins on their surface. Conditioned media from EPO-primed mobPBSCs significantly enhanced migration and tube formation of endothelial 
cells. Also, EPO-primed mobPBSCs itself showed a stronger adhesion to endothelial cells or fibronectin. In vivo models showed evidence of increased 
vessel formation after injection of EPO-primed mobPBSCs and direct incorporation of human mobPBSCs into mouse vasculature in the ischemic limb 
at 21 days after cell implantation.
Conclusions:  Brief ex-vivo EPO-priming is a novel method to augment the vasculogenic potential of human mobPBSCs by induction of angiogenic 
cytokines and adhesion molecules, which would be helpful to achieve better results after intracoronary infusion in patients with myocardial 
infarction.
